CoChat

US academic drug discovery

Open access
Frye, Stephen, Crosby, Marina, Edwards, Teresa, Juliano, Rudolph · 2011 · Nature Reviews Drug Discovery
Cited by 101

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Progress in the biomedical sciences has accelerated enormously over the last two decades. Technology to enable discovery of ligands to perturb the function of biological targets has also advanced such that many complementary approaches exist for creating small molecule tools to interrogate biological processes and potentially serve as drug leads.1 However, while pharmaceutical industry investment in R&D has grown exponentially, approval of new medicines has remained constant2 and pricing pressures and litigation have further eroded profitability.3 Frequent mergers, reorganizations and reductions in scientific staff in the for-profit drug discovery sector have made it increasingly difficult for a research project or strategy to bear fruit before it is abandoned for nontechnical reasons.4 As a result, there is a growing trend for large pharmaceutical companies to externalize the early phases of drug discovery via either active partnerships or opportunistic in-licensing of novel compounds. In this context, there is a clear societal need for enhanced innovation and productivity in drug discovery in order for advances in biomedical research to result in new medicines. Academia is a critical area where innovation in drug discovery can flourish. Indeed, two recent reviews provided strong support for the role of academics and biotechnology companies (often spawned from academia) in producing 56% of the new small molecule and biologic drugs judged by the FDA to warrant priority review in the period spanning 1998-2007.5, 6 While over the years individual investigators in academia have been successful at small molecule drug discovery, the conditions outlined above have led to more formal academic drug discovery (ADD) efforts during the last decade. This trend has been noted and a number of scientists engaged in this endeavor have provided commentary on the emerging field.7-11 However, the analyses to date have relied almost exclusively on expert opinion and very rarely upon data. In the current article we report the results of a scientific survey of academic and non-profit drug discovery entities in the United States and our analysis of the current state of this enterprise and prospects for the future. We intentionally excluded work on large molecules such as monoclonal antibodies or siRNA because our intent was to capture the emerging trend of systematic focus on small molecule drug discovery. To accomplish this we utilized survey methodology currently employed in organizational and general social science research, as described in the Supplementary Materials. Seventy-eight units were identified as small molecule drug discovery centers sited within universities or non-profit research organizations and our response rate was 71% which compares very favorably to average response rates in web surveys.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrd3462

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 101

Metadata

Authors
Frye, S., Crosby, M., Edwards, T., & Juliano, R.
Venue
Nature Reviews Drug Discovery
Published
2011-06
Volume
10
Issue
6
Pages
409-410
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W1994711206
Cited by
101
References
2
FWCI
34.62
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: US academic drug discovery. https://app.cochat.ai/papers/10.1038/nrd3462
The paper
Frye, S., Crosby, M., Edwards, T., & Juliano, R. (2011). US academic drug discovery. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd3462

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.